LA JOLLA, Calif.--(BUSINESS WIRE)--Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of stem cell-based delivery of oncolytic viruses, announced today its selection as a finalist for presentation during the Innovation Showcase at the upcoming annual Oncolytic Virotherapy Summit, which will be held October 26 through October 28, 2021, in Boston, MA.
For the first time, the Oncolytic Virotherapy Summit will host the Oncolytic Virotherapy Innovation Showcase. Calidi Biotherapeutics has been selected as one of the 10 finalists to present its novel platform technology to the entire summit audience during the Pre-Conference Focus Day.
“We are very pleased with the decision of the prestigious selection committee to invite Calidi to present our stem cell-based technology for delivery and potentiation of oncolytic viruses,” said Boris Minev, MD, President of Medical and Scientific Affairs at Calidi Biotherapeutics. “This meeting presents a valuable opportunity to understand the latest advances in our field and explore collaborative opportunities with potential clinical, academic, and industry partners. Ultimately, Calidi’s participation in this summit provides a significant platform to share our novel technology with a target audience both highly focused and experienced in our field.”
Calidi’s presentation at the Oncolytic Virotherapy Innovation Showcase will focus on its proprietary stem cell-based delivery systems, shown to effectively protect, amplify, and potentiate oncolytic viruses from elimination by the patient’s immune system. The therapeutic utility of Calidi’s novel technology platforms is supported by clinical findings, published in The Lancet Oncology and Journal of Translational Medicine.
About Calidi Biotherapeutics
Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology that is revolutionizing the effective delivery of oncolytic viruses for targeted therapy against difficult-to-treat cancers. Calidi Biotherapeutics is advancing a potent allogeneic stem cell and oncolytic virus combination for use in multiple oncology indications. Calidi’s off-the-shelf, universal cell-based delivery platform is designed to protect, amplify, and potentiate oncolytic viruses currently in development leading to enhanced efficacy and improved patient safety. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit calidibio.com.
About the Oncolytic Virotherapy Summit
Now in its sixth year, the Oncolytic Virotherapy Summit is the industry’s definitive guide to turning viral vehicles into clinically effective therapeutics across oncology indications. With three days of in-depth, cutting-edge case studies and the highest caliber of industry discussions, the OV Summit will provide the roadmap to oncolytic virotherapy market success. This year, over 100+ drug developers will converge at the OV Summit to disseminate the latest findings, build a comprehensive network of like-minded peers who share the same challenges, and search for the latest combination and genetic engineering strategies. For additional information, visit oncolytic-virotherapy-summit.com.
Some of the statements in this press release may be forward-looking statements that involve risks and uncertainties inherent in research and development. Such forward-looking statements include the expectations, plans, and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. No forward-looking statement can be guaranteed. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control. Calidi Biotherapeutics does not make any representation or warranty, express or implied, as to the completeness or updated status of such statements.